Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia
- 5 March 2018
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 2 (5) , 529-533
Abstract
Key Points: Fifteen percent of NCI high-risk, Ph-negative, B-ALL patients harbored a kinase-activating fusion, and often associated with IKZF1 deletion. IKZF1 deletion represents an independent prognostic factor of poor outcomes, regardless of fusion-positivity.Keywords
This publication has 11 references indexed in Scilit:
- Philadelphia chromosome–like acute lymphoblastic leukemiaBlood, 2017
- Targetable kinase gene fusions in high-risk B-ALL: a study from the Children’s Oncology GroupBlood, 2017
- Ph-like acute lymphoblastic leukemiaHematology-American Society Hematology Education Program, 2016
- Treatment of Childhood Acute Lymphoblastic Leukemia: Prognostic Factors and Clinical AdvancesCurrent Hematologic Malignancy Reports, 2016
- Intravenous pegylated asparaginase versus intramuscular native Escherichia coli l-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trialThe Lancet Oncology, 2015
- Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic LeukemiaNew England Journal of Medicine, 2014
- Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALLBlood, 2013
- Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemiaBlood, 2012
- IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocolHaematologica, 2012
- Improved Survival for Children and Adolescents With Acute Lymphoblastic Leukemia Between 1990 and 2005: A Report From the Children's Oncology GroupJournal of Clinical Oncology, 2012